Florence Laigle-Donadey1, Jean-Yves Delattre. 1. Service de Neurologie Mazarin, Hôpital de la Pitié-Salpêtrière - Assistance Publique-Hôpitaux de Paris, Paris, France. florence.laigle-donadey@psl.ap-hop-paris.fr
Abstract
PURPOSE OF REVIEW: This review updates available data on the management of gliomas in the elderly. RECENT FINDINGS: Prospective randomized studies have recently established the benefit of radiotherapy and the validity of an accelerated course of irradiation in older patients with malignant gliomas. SUMMARY: The incidence of gliomas is increasing in the elderly population. Unfortunately, increasing age is one of the most consistent negative prognostic factors in gliomas and the optimal management of this population remains unsettled since patients aged 65 years or more are usually excluded from clinical trials. The previous nihilistic approach is progressively changing towards more active strategies with recent evidence that older patients (70-80 years) may benefit from surgery, radiotherapy, or chemotherapy. Initial performance status, quality of life, and concomitant pathologies are important factors to consider before treatment onset. In the future, it will be necessary to design specific schedules of treatment in this population.
PURPOSE OF REVIEW: This review updates available data on the management of gliomas in the elderly. RECENT FINDINGS: Prospective randomized studies have recently established the benefit of radiotherapy and the validity of an accelerated course of irradiation in older patients with malignant gliomas. SUMMARY: The incidence of gliomas is increasing in the elderly population. Unfortunately, increasing age is one of the most consistent negative prognostic factors in gliomas and the optimal management of this population remains unsettled since patients aged 65 years or more are usually excluded from clinical trials. The previous nihilistic approach is progressively changing towards more active strategies with recent evidence that older patients (70-80 years) may benefit from surgery, radiotherapy, or chemotherapy. Initial performance status, quality of life, and concomitant pathologies are important factors to consider before treatment onset. In the future, it will be necessary to design specific schedules of treatment in this population.
Authors: Kaisorn L Chaichana; Khan K Chaichana; Alessandro Olivi; Jon D Weingart; Richard Bennett; Henry Brem; Alfredo Quiñones-Hinojosa Journal: J Neurosurg Date: 2010-10-01 Impact factor: 5.115
Authors: Jacob G Scott; Luc Bauchet; Tyler J Fraum; Lakshmi Nayak; Anna R Cooper; Samuel T Chao; John H Suh; Michael A Vogelbaum; David M Peereboom; Sonia Zouaoui; Hélène Mathieu-Daudé; Pascale Fabbro-Peray; Valérie Rigau; Luc Taillandier; Lauren E Abrey; Lisa M DeAngelis; Joanna H Shih; Fabio M Iwamoto Journal: Cancer Date: 2012-04-19 Impact factor: 6.860
Authors: Mario Balducci; Alba Fiorentino; Pasquale De Bonis; Silvia Chiesa; Stefania Manfrida; Giuseppe Roberto D'Agostino; Giovanna Mantini; Vincenzo Frascino; Gian Carlo Mattiucci; Berardino De Bari; Annunziato Mangiola; Francesco Miccichè; Maria Antonietta Gambacorta; Gabriella Colicchio; Alessio Giuseppe Morganti; Carmelo Anile; Vincenzo Valentini Journal: Med Oncol Date: 2012-06-07 Impact factor: 3.064
Authors: Teri N Kreisl; Lyndon Kim; Kraig Moore; Paul Duic; Cheryl Royce; Irene Stroud; Nancy Garren; Megan Mackey; John A Butman; Kevin Camphausen; John Park; Paul S Albert; Howard A Fine Journal: J Clin Oncol Date: 2008-12-29 Impact factor: 44.544
Authors: Joonas Haapasalo; Mika Hilvo; Kristiina Nordfors; Hannu Haapasalo; Seppo Parkkila; Alise Hyrskyluoto; Immo Rantala; Abdul Waheed; William S Sly; Silvia Pastorekova; Jaromir Pastorek; Anna-Kaisa Parkkila Journal: Neuro Oncol Date: 2008-03-05 Impact factor: 12.300
Authors: Clemens Seidel; Nils Dörner; Matthias Osswald; Antje Wick; Michael Platten; Martin Bendszus; Wolfgang Wick Journal: BMC Cancer Date: 2011-04-12 Impact factor: 4.430